WATERLOO, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Client Outlook, a leading provider of FDA Class II clinical and diagnostic image viewing solutions, announced today its partnership with Medidata to support the use of medical imaging in clinical trials.
The Medidata Cloud is the most used unified platform in life sciences for clinical development, commercial, and real-world data. Powered by artificial intelligence, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies and academic researchers accelerate value, minimize risk and optimize outcomes.
The use of medical imaging data as an endpoint in clinical trials is becoming increasingly important due to its critical role in determining disease state and progression, especially in therapeutic areas like oncology where nearly all trials rely on imaging. Medidata selected eUnity™ to help manage medical images based on its HTML5-based zero-footprint architecture which demonstrated superior ability to tightly integrate with the Medidata Cloud.
eUnity is the industry’s first Smartviewer; an adaptable zero-footprint software platform that combines advanced image viewing and integration capabilities. Its progressive architecture facilitates interoperability with diverse technologies, while powerful hanging protocols and MIP/MPR/3D advanced visualization functionality meet the performance demands for diagnostic radiology reading and breast imaging. eUnity requires no specialized hardware and needs only minimal resources to deploy, making it an ideal solution for a cloud platform.
“The use of medical imaging in clinical trials continues to expand and our partners and sponsors need powerful image viewing capabilities to manage and assess images at any point in a clinical trial,” said Dan Braga, Senior Director of Medical Imaging at Medidata. “eUnity was a natural choice to plug into our platform due to its zero-footprint architecture, powerful image assessment tools, and measurement export capabilities.”
“The parallels between Client Outlook and Medidata make for a perfect union,” said Steve Rankin, President and CEO, Client Outlook. “We both specialize in what we do – using a single platform design approach to develop highly adaptable solutions that improve productivity and deliver appreciable clinical value.” Rankin added; “We are thrilled to partner with Medidata in the life sciences sector to show our breadth and scalability in a new market area that has such an important social impact.”
About Client Outlook
Client Outlook Inc. is a healthcare technology company focused exclusively on empowering the image viewing evolution from hospital department to healthcare enterprise through an innovative software platform called eUnity. Uniquely designed as a zero-footprint viewing solution but purpose-built as an integration platform, eUnity gives all patient care stakeholders equal access to images for clinical viewing and diagnostic radiology reading. This powerful foundation cultivates a boundary-less enterprise that manages change and is prepared for future growth. Visit www.clientoutlook.com to learn more.
About Medidata
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
For more information, please contact:
John Marshall
Vice President, Sales and Marketing, Client Outlook
john.marshall@clientoutlook.com
315-278-0023
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.